Undetectable levels of HIV is untransmittable, say experts

Image
ANI Washington D.C. [USA]
Last Updated : Jan 12 2019 | 12:30 PM IST

Officials from the National Institutes of Health have said that the results from years of clinical evidence that firmly established that the HIV Undetectable = Untransmittable (U=U) concept is scientifically sound.

According to the experts, U=U means people living with HIV who are able to achieve and maintain an undetectable viral load, i.e., the amount of HIV in the blood, by taking and adhering to antiretroviral therapy (ART) as prescribed cannot sexually transmit the virus to others.

The results, published in Journal of the American Medical Association (JAMA), saw officials from NIH's National Institute of Allergy and Infectious Diseases (NIAID) review the scientific evidence underlying the theory and discussing the implications of widespread acceptance of the message.

The new commentary saw NIAID Director Anthony S. Fauci, M.D., and colleagues summarize results from large clinical trials and cohort studies validating U=U. The landmark NIH-funded HPTN 052 clinical trial showed that no linked HIV transmissions occurred among HIV affected heterosexual couples when the partner living with HIV had a durably suppressed viral load.

Subsequently, the PARTNER and Opposites Attract studies confirmed these findings and extended them to male-male couples.

The NIAID officials note that the validation of the HIV treatment as prevention strategy and acceptance of the U=U concept as scientifically sound have numerous behavioural, social and legal implications and can help control the HIV pandemic by preventing HIV transmission as it can reduce the stigma that many people with HIV face.

The success of U=U as an HIV prevention method depends on achieving and maintaining an undetectable viral load by taking ART daily as prescribed. However, there are multiple factors that can often make ART adherence difficult. To enhance the overall success of U=U, the authors emphasise the importance of implementing programmes that help patients remain in care and address the barriers to daily therapy.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 12 2019 | 12:20 PM IST

Next Story